1,192,595 Shares in Enovis Co. (NYSE:ENOV) Purchased by River Road Asset Management LLC

River Road Asset Management LLC purchased a new stake in shares of Enovis Co. (NYSE:ENOV - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,192,595 shares of the company's stock, valued at approximately $51,341,000. River Road Asset Management LLC owned approximately 2.14% of Enovis as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Fidelis Capital Partners LLC bought a new stake in Enovis in the first quarter worth $34,000. Ridgewood Investments LLC bought a new position in shares of Enovis during the second quarter valued at $44,000. DekaBank Deutsche Girozentrale bought a new position in shares of Enovis during the third quarter valued at $55,000. Innealta Capital LLC bought a new position in shares of Enovis during the second quarter valued at $65,000. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock valued at $76,000 after purchasing an additional 371 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Stock Performance

ENOV traded up $0.29 during midday trading on Tuesday, reaching $43.32. The company had a trading volume of 891,517 shares, compared to its average volume of 574,950. The company has a quick ratio of 1.08, a current ratio of 2.26 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average of $42.21 and a two-hundred day moving average of $45.71. The company has a market cap of $2.42 billion, a P/E ratio of -25.92 and a beta of 1.91. Enovis Co. has a 1 year low of $38.27 and a 1 year high of $65.03.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.62 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.03. The business had revenue of $525.20 million during the quarter, compared to analysts' expectations of $525.99 million. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. The business's quarterly revenue was up 22.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.61 earnings per share. As a group, equities research analysts predict that Enovis Co. will post 2.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Evercore ISI lowered their price target on Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a report on Tuesday, October 1st. JMP Securities started coverage on Enovis in a report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price target on the stock. Needham & Company LLC reduced their price objective on Enovis from $82.00 to $65.00 and set a "buy" rating for the company in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. reduced their price objective on Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $67.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.